Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Pharmanovia","sponsor":"Aquestive Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant\u2122 (diazepam) Buccal Film for European and MENA Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","amount":"$167.0 million","upfrontCash":"$66.0 million","newsHeadline":"Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi\u00ae (solriamfetol) in Europe","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Sleep","graph2":"Approved"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Closed Loop Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Closed Loop Medicine and Pharmanovia Enter a Co-Development Partnership for Precision Medicine Combination Therapeutics","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Stealth Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Global Territories","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III"},{"orgOrder":0,"company":"Pharmanovia","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Pharmanovia

    Menu

    Pharmanovia

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Pharmanovia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi

              Details:

              Pharmanovia expands its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from Sanofi, including Frisium (clobazam), Gardenal (phenobarbital), Tercian (cyamemazine), Stemetil, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren and Castilium.

              Lead Product(s): Clobazam

              Therapeutic Area: Psychiatry/Psychology Product Name: Frisium

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Sanofi

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Divestment September 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pharmanovia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Stealth BioTherapeutics Enters into Exclusive Licensing Agreement with Pharmanovia to Commercialize Elamipretide for the Treatment of Barth Syndrome in Europe and Key Globa...

              Details:

              Pharmanovia will commercialize MTP-131 (elamipretide), an investigational mitochondrial protective agent, in Europe for the treatment of Barth syndrome, an ultra-rare cardiac condition caused by mitochondrial cardiolipin deficiency for which there are no approved treatments.

              Lead Product(s): Elamipretide

              Therapeutic Area: Rare Diseases and Disorders Product Name: MTP-131

              Highest Development Status: Phase III Product Type: Peptide

              Recipient: Stealth Biotherapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement May 30, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pharmanovia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Closed Loop Medicine and Pharmanovia Enter a Co-Development Partnership for Precision Medicine Combination Therapeutics

              Details:

              Under the partnership, Closed Loop’s proprietary Software-as-a-Medical Device dosing optimization technology will be combined with Pharmanovia’s established anti-hypertensive medicines to develop drug + software product solutions for the treatment of hypertension.

              Lead Product(s): Undisclosed

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Recipient: Closed Loop Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pharmanovia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

              Details:

              Under the agreement, Pharmanovia will be responsible for the development and marketing of Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults with EDS due to narcolepsy or OSA, in Europe and MENA regions.

              Lead Product(s): Solriamfetol Hydrochloride

              Therapeutic Area: Sleep Product Name: Sunosi

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Axsome Therapeutics

              Deal Size: $167.0 million Upfront Cash: $66.0 million

              Deal Type: Licensing Agreement February 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Pharmanovia

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets

              Details:

              Libervant™ is a buccally, administered film formulation of diazepam, intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.

              Lead Product(s): Diazepam

              Therapeutic Area: Neurology Product Name: Libervant

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Aquestive Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY